

CORPORATE NEWS

MeVis Q2 2016: Operative stability at a high level

Again improvement in revenues in the Digital Mammography segment

- Revenues in the second quarter with € 3.8 m almost identical to previous year (€3.7 m)
- Earnings before interest and taxes (EBIT) in the second quarter with € 1.1 m also at level of previous year, 29 % EBIT-margin
- Financial result increased slightly in the second quarter compared to previous year from €0.3 m to €0.5 m

Bremen, August 23, 2016 – MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading provider of medical imaging software, today announced its figures for the first half of 2016.

Sales in the second quarter of 2016 amounted to € 3,795 k, up 2 % compared to the same quarter in 2015 (€ 3,730 k). As a result, sales rose year on year to €7,671 k (prev. year: € 7,138 k) in the first half of the year. Sales in the new license business fell by 2 % to € 3,246 k, while sales in the maintenance business grew by 25 % to € 3,839 k, now accounting for 50 % of total sales. Sales in the Digital Mammography segment were up by 8 % to € 6,114 k (prev. year: € 5,637 k), while sales in the Other Diagnostics segment grew slightly by 4 % to € 1,557 k (prev. year: € 1,501 k).

*Sales in second quarter
year on year increased
by 2 %*

Operating costs increased in the second quarter of 2016 due to slightly higher staff costs, which were up 4 % in the second quarter among other things on account of new hires. This corresponds to a cumulative increase of 1 % in the first half of the year. In the second quarter, other operating expenses rose marginally year on year to € 474 k (prev. year: € 453 k). Cumulated for the first half of 2016, other operating expenses remained stable year on year.

*Operating costs increased
slightly*

Depreciation and amortization came to € 899 k (down 14 % year on year, primarily due to lower scheduled write-downs on capitalized development costs), resulting in EBIT (earnings before interest and taxes) of € 2,293 k (up a significant 41 % on the

previous year's figure of € 1,627 k) for the reporting period and a corresponding EBIT margin of 30 % (prev. year: 23 %).

The financial result decreased from € 428 k year on year to € -367 k. Negative effects from the development of the US dollar exchange rate, combined with a high share of liquidity in US dollars, were largely responsible for this.

Due to the fiscal unity, which became effective as of January 1, 2016, the tax expense consisted solely of capital income tax amounting to € 5 k (prev. year: tax expense of € 787 k). After-tax earnings consequently rose by € 653 k to € 1,921 k, which is equivalent to undiluted earnings per share of € 1.06 (prev. year: € 0.72).

*Net profit increased from
€ 1,268 k to € 1,921 k,
€ 1.06 earnings per share in
the first half*

The financial reports of the Company can be downloaded from the following website: <http://www.mevis.de/en/investor-relations/financial-reports/>

MeVis Medical Solutions AG was founded in 1997 and is one of the world's leading independent developer and provider of medical imaging software with focus on dedicated, disease-oriented clinical applications. MeVis AG has been listed on the Frankfurt Stock Exchange in the Prime Standard segment of the Regulated Market since November 16, 2007.

Over the past few years, there has been an enormous increase in the complexity and volume of medical imaging data derived from diagnostic imaging processes such as digital mammography, computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound (US). MeVis' products analyze and process this data in such a way as to provide medical professionals with crucial information for early detection, diagnosis and intervention in the areas of cancer and lung diseases as well as neurological disorders. The Company develops its software solutions in close consultation with world's leading medical experts and original equipment manufacturers (OEM) in the medical technology sector and primarily markets this software via these partnerships.